Background: In 2007, the National Cancer Center Hospital East (NCCHE) became the first hospital in Japan to provide an outpatient pharmacy service in which pharmacists worked with oncologists in an outpatient clinic booth. Purpose: This retrospective cohort study was undertaken to evaluate the economic effects of the clinical pharmacy service for outpatients. Methods: We investigated pharmacist interventions for chemotherapy patients between June 2016 and November 2016 using intervention diaries and patient medical records. Results: A total of 2,177 business hours were accumulated by six pharmacists over 6 months. Of the total 9,775 outpatient visits, pharmacists worked for 5,142 (53%) oncologist outpatient clinics which pharmacists evaluated as warranting interventions, particularly chemotherapy cases. In this period, the number of pharmacists' suggestions for prescriptions from economic perspectives to save medication costs was 199. The acceptance rate was 91% (n ¼ 181) and contents involved: reviewing patients taking multiple agents and suggesting adjustments to the number of prescribed medicines (n ¼ 113); reviewing medicine use and suggesting cheaper medications (n ¼ 59); reviewing and suggesting reductions in dosages (n ¼ 19); reviewing medicine use and suggesting stopping anticancer medicine (n ¼ 4); and dosage rounding and adjusting anticancer medicines (n ¼ 3). The overall saving was 6,984,637 yen, comprising 5,842,061 yen from anticancer agents, 1,086,484 yen from regularly used non-anticancer medicines, 16,704 yen from medicines used in cases in which patients had adverse reactions or annoying symptoms, and 39,388 yen from premedications. Conclusions: This study clarified that a high rate of pharmacist interventions achieved more than 100,000 U.S. dollars in economic impact in 1 year. These results confirm an economic benefit from the new pharmacy service in Japan. Division of Gastroenterology, University of Tsukuba Background: Pmab and Cmab are known to be effective in KRAS WT mCRC. Recent study showed that Pmab and Cmab monotherapy were comparable in pts with KRAS WT mCRC previously treated with FU-, L-OHP-, and IRI-based chemotherapies. However, it is not clear whether their combination therapy with IRI confers similar benefit. Methods: Pts with KRAS WT mCRC previously treated with FU-, L-OHP-, and IRIbased chemotherapies were randomized 1:1 to either Cmab þ IRI(Cmab arm), or Pmab þ IRI(Pmab arm). Primary objective was progression free survival (PFS), with an expected hazard ratio (HR) of 1.0 with non-inferiority margin of 1.3 (80% CI) using cox proportional hazards model. Median PFS with both arms were assumed to be 6.0 months. Secondary objectives were overall survival (OS), response rate (RR), disease control rate (DCR), and safety. Results: From Dec. 2011 to Sep. 2014, 121 pts were enrolled from 31 sites in Japan, and 1 patient declined before treatment. Totally, 120 (Cmab arm: 59, Pmab arm 61) pts were eligible for efficacy analysis. Baseline characteristics were well balanced between the two arms. 96.7% of the pts were previously treated with bevacizumab. Median PFS was 4.3 months in Cmab arm and 5.4 months in Pmab arm, showing non-stratified HR of 0.68 (95% confidential interval (CI): 0.47-0.99, p-value <0.001 for non-inferiority, and 0.040 for superiority). OS in Cmab and Pmab arm were 11.5 vs 14.9 months (HR: 0.68, 95% CI: 0.46-1.02, p < 0.001 for non-inferiority, p ¼ 0.062 for superiority). RR in Cmab and Pmab arm were 22.0 and 26.2%, and DCR were 74.6 and 82.0%, respectively. The common grade 3 or 4 adverse events in Cmab/Pmab arm were leukopenia 19.0/ 3.3%, neutropenia 27.6/8.3%, hypomagnesaemia 6.9/16.7%, and rash 5.2/13.3%, respectively.
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Conclusion:
Non-inferiority of Pmab to Cmab in combination with IRI was suggested for patients with KRAS WT mCRC previously treated with FU-, L-OHP-, and IRIbased chemotherapies, associated with better PFS and OS.
SPS À 7 Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial . Preliminary OS data favoured N; objective tumour response was observed in 59% of the N arm vs 44% of the P arm (all partial responses). All pts experienced at least one adverse event (AE; any grade), with 7% of the N arm discontinuing due to AEs vs 15% with P. Serious AEs occurred in 36% vs 42% of pts in the N and P arms, respectively. The most common Grade !3 AEs (N vs P) were neutropenia (34% vs 10%), alanine aminotransferase increase (14% vs 2%) and gamma glutamyltransferase increase (14% vs 0%). Conclusion: NþPEM/CIS demonstrated clinical efficacy with improved PFS and a tolerable safety profile in pts with unresectable MPM. Based on these promising findings, the study was extended and the Phase III part is recruiting (NCT01907100). Background: Nivolumab is a standard of care treatment for previously treated, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC), but real-world safety evidence after launch in Japan is limited. Methods: In Japan, post-marketing All-Case Surveillance of nivolumab is currently underway in patients with NSCLC enrolled from December 17, 2015 to March 31, 2016. The data were collected from all NSCLC patients treated with nivolumab in Japan whose case report forms were available by November 30, 2016. Interim data analysis was conducted. Results: Of 1005 NSCLC patients, median of treatment period was 43.0 days (1 to 323 days). There were 653 adenocarcinoma (65.0%) and 288 squamous cell carcinoma (28.7%), 597 aged >65 (59.4%), 711 male (70.7%), and 439 with a history of radiation therapy (43.7%). Patients with ECOG performance status (PS) of 2-4 and patients with preexisting autoimmune disorders, who were not eligible to participate in most clinical trials, accounted for 25.3% (n ¼ 254) and 1.3% (n ¼ 13), respectively. The incidence of drug-related adverse events (AEs) of any grade was 34.4% (n ¼ 346), grade 3-4 was V C Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. 
